CytoMed Therapeutics’ Chairman’s Effective Shareholding Climbs to 21.95%

SINGAPORE, Oct. 22, 2025 — CytoMed Therapeutics (NASDAQ: GDTC) (“CytoMed” or the “Company”), a clinical-stage biopharmaceutical firm based in Singapore that specializes in developing affordable, donor-derived cell-based immunotherapies for a broad spectrum of cancers, including both blood and solid tumors, announced today that its Executive Chairman and significant shareholder, Mr. Peter Choo, has boosted his stake in the Company. This increase follows recent open-market acquisitions of 105,824 shares. These new purchases are in addition to the 187,500 shares he already holds personally, elevating his direct ownership in CytoMed to 2.50% as of this date. Furthermore, Mr. Choo also holds a 55% ownership in Glorious Finance Limited and is the sole shareholder of EP Capital Inc., entities that collectively own 2,282,422 shares, accounting for 19.45% of the Company. In total, his effective shareholding now amounts to 2,388,246 shares, representing 21.95% of the Company’s entire outstanding shares.

Commenting on his investment, Chairman Peter remarked, “I recognize the inherent value and significant potential within our innovative proprietary technologies, which aim to deliver affordable, ‘off-the-shelf’ cancer treatments. This aligns with the growing investor interest in biotherapeutics across Asia, particularly in China. Moreover, Southeast Asia’s expanding healthcare and medical tourism sectors, alongside the escalating healthcare costs in Western countries, create distinct opportunities for entities capable of pioneering solutions that offer cost-effective patient access. The robust biotech growth, increasing M&A activity, and supportive regulatory landscape in the region further solidify my decision to invest.”

The Company intends to release updates regarding any subsequent share purchases by its Chairman as they become available. Shareholders and investors are cautioned to exercise prudence when trading the Company’s securities until further announcements are issued.

About CytoMed Therapeutics Limited (CytoMed)

Established in 2018, CytoMed originated as a spin-off from the Agency for Science, Technology and Research (A*STAR), Singapore’s principal public sector research and development body. CytoMed functions as a clinical-stage biopharmaceutical firm dedicated to leveraging its proprietary licensed technologies, specifically gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell approaches, to develop innovative allogeneic cell-based immunotherapies for a spectrum of human cancers. The drive behind these novel technological advancements stems from the proven clinical efficacy of current CAR-T therapies in addressing haematological malignancies, coupled with the existing clinical constraints and commercial hurdles involved in extending the CAR-T concept to treat solid tumors. For additional details, please visit www.cytomed.sg and connect with us on Twitter (“X”) @CytomedSG, LinkedIn, and Facebook.

Forward-Looking Statements
This press release features forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995. Such statements encompass plans, objectives, goals, strategies, anticipated future events or performance, underlying assumptions, and other declarations that go beyond historical facts. The Company signals forward-looking statements by employing terms like “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or comparable phrases that are not exclusively historical. Forward-looking statements do not assure future performance and carry inherent risks and uncertainties that could lead to actual outcomes differing significantly from the Company’s stated expectations. These statements are contingent upon various uncertainties and risks, including but not limited to: the Company’s strategies for developing and marketing its product candidates; the initiation, scheduling, advancement, and outcomes of the Company’s ongoing and forthcoming preclinical and clinical trials, as well as its R&D initiatives; the Company’s projections concerning expenditures, future revenues, capital demands, and requirements for supplementary funding; the Company’s capacity to successfully obtain or license additional product candidates under fair terms; the Company’s capability to forge and sustain collaborations and/or secure additional financing, along with assumptions underlying or related to any of the aforementioned, and other risks detailed in the Company’s reports filed with the SEC. Consequently, investors are advised against placing excessive reliance on any forward-looking statements within this press release. Further factors are elaborated in the Company’s SEC filings, accessible at www.sec.gov. The Company disclaims any obligation to publicly update or revise these forward-looking statements in response to events or circumstances occurring after this date.

Contact Information:

CytoMed Therapeutics Limited
enquiry@cytomed.sg
For the attention of: Evelyn Tan, Chief Corporate Officer